Small molecules as therapeutic drugs for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
&NA; Mitochondrial dysfunction is a central protagonist of Alzheimer's disease (AD) pathogenesis. Mitochondrial dysfunction stems from various factors including mitochondrial DNA damage and oxidative stress from reactive oxygen species, membrane and ionic gradient destabilization, and interaction with toxic proteins such as amyloid beta (A&bgr;). Therapeutic drugs such as cholinesterase and glutamate inhibitors have proven to improve synaptic neurotransmitters, but do not address mitochondrial dysfunction. Researchers have demonstrated that oxidative damage may be reduced by increasing endogenous antioxidants, and/or increasing exogenous antioxidants such as vitamin C & E, beta‐carotene and glutathione. Nonetheless, as AD pathology intensifies, endogenous antioxidants are overwhelmed, and exogenous antioxidants are unable to reach neuronal mitochondria as they are blocked by the blood brain barrier. Current therapeutic methods however include novel usage of lipophilic phosphonium cation bound to antioxidants, to effect neuronal mitochondria targeted activity. Mitochondria targeted MitoQ, MitoVitE, MitoTempo, MitoPBN and MCAT concentrate within mitochondria where they scavenge free‐radicals, and augment mitochondrial dysfunction. Additional molecules include Szeto‐Schiller (SS) peptides which target stability of the inner mitochondrial membrane, and DDQ molecule capable of improving bioenergetics and reduce mitochondrial fragmentation. This article discusses advantages and disadvantages of small molecules, their ability to mitigate A&bgr; induced damage, and ability to ameliorate synaptic dysfunction and cognitive loss. HighlightsMitochondria are power houses of cells and important for cell survival and cell death.Mitochondrial dysfunction has been implicated in aging and age‐related neurodegenerative diseases.Natural antioxidants such as vitamin C & E, beta‐carotene and glutathione have protective properties with limited blood brain barrier capacity.Mitochondria targeted molecules such as MitoQ, MitoVitE, MitoTempo, MitoPBN and SS31 concentrate within mitochondria where they scavenge free‐radicals, and augment mitochondrial dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Extension of murine life span by overexpression of catalase targeted to mitochondria
Schriner, S. E., Linford, N. J., Martin, G. M., Treuting, P., Ogburn, C. E., Emond, M., Coskun, P. E., Ladiges, W., Wolf, N., Van Remmen, H., et al. (2005) · Science · doi:10.1126/science.1106653 · Cited by 1,724 · cited 4×
“There was a measured 25% reduction in H2O2 production by mitochondria in cardiac muscles, and these cardiac muscles also showed significantly less arteriosclerosis and myopathy compared to wild-type control (Schriner et al., 2005).”
InfluentialOxidative stress and mitochondrial dysfunction in Alzheimer’s disease
Wang, X., Wang, W., Li, L., Perry, G., Lee, H.-G., & Zhu, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.015 · Cited by 1,357
Reddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975
Self-citationMitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · cited 10×
“Oxidative damage contributes to mtDNA and nDNA damage, mutation, and loss of mtDNA copy number (Swerdlow et al., 2013; Manczak et al., 2018; Kerr et al., 2017).”
InfluentialEarly deficits in synaptic mitochondria in an Alzheimer's disease mouse model
Du, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M., & ShiDu Yan, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006586107 · Cited by 704
Calkins, M. J., Manczak, M., Mao, P., Shirendeb, U., & Reddy, P. H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr381 · Cited by 646
Self-citationMitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., Szeto, H. H., Park, B., & Reddy, P. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100564 · Cited by 469
Self-citationSelective targeting of an antioxidant to mitochondria
Smith, R. A. J., Porteous, C. M., Coulter, C. V., & Murphy, M. P. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00543.x · Cited by 466 · cited 10×
“Also like MitoQ, MitoVitE may accumulate in high concentration in mitochondria, up to 5000–6000 units as demonstrated by Smith's research team in 1999 by incubating mitochondria with 20 μM MitoVitE (Reddy, 2008; Smith et al., 1999).”
Influential
Research works printed but not linked: 58
- Alexeyev, 2013, The maintenance of mitochondrial DNA integrity—critical analysis and update, Cold Spring Harb. Perspect. Biol., 5, a012641, 10.1101/cshperspect.a012641 · DOI · Paper page
- Angajala, 2018, Diverse roles of mitochondria in immune responses: novel insights into Immuno-metabolism, Front. Immunol., 9, 10.3389/fimmu.2018.01605 · DOI · Paper page
- Apak R, Guclu K, Demirata B, Ozyurek M, Celik SE, Bektasoglu B, Berker KI, Ozyurt (2007) Comparative evaluation of various total antioxidant capacity assays applied to phenolic compounds with the CUPRAC assay. Molecules. 12(7):1496–1547 doi:https://doi.org/10.3390/12071496. · DOI · Paper page
- Apostolova, 2015, Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications, Antioxid. Redox Signal., 22, 686, 10.1089/ars.2014.5952 · DOI · Paper page
- Battogtokh, 2018, Park SJ (2018) mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives, Acta Pharm. Sin. B, 8, 862, 10.1016/j.apsb.2018.05.006 · DOI · Paper page
- Bernardi, 2015, The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection, J. Mol. Cell. Cardiol., 78, 100, 10.1016/j.yjmcc.2014.09.023 · DOI · Paper page
- Birk, 2015, Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia, Biochimica et Biophysica Acta (BBA) – Bioenergetics, 1847, 1075, 10.1016/j.bbabio.2015.06.006 · DOI
- Blair, 2015, The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease, J. Neurochem., 133, 1, 10.1111/jnc.13033 · DOI · Paper page
- Blanco-Silvente, 2017, Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients, Int. J. Neuropsychopharmacol., 20, 519, 10.1093/ijnp/pyx012 · DOI · Paper page
- Cai, 2016, Alterations in mitochondrial quality control in Alzheimer's disease, Front. Cell. Neurosci., 10, 10.3389/fncel.2016.00024 · DOI · Paper page
- Caspersen, 2005, Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease, FASEB J., 19, 2040, 10.1096/fj.05-3735fje · DOI · Paper page
- Chaturvedi, 2013, Mitochondrial diseases of the brain, Free Radic. Biol. Med., 63, 1, 10.1016/j.freeradbiomed.2013.03.018 · DOI · Paper page
- Chelikani, 2004, Diversity of structures and properties among catalases, Cell. Mol. Life Sci., 61, 192, 10.1007/s00018-003-3206-5 · DOI · Paper page
- Chen, 2017, More insight into BDNF against neurodegeneration: anti-apoptosis, anti-oxidation, and suppression of autophagy, Int. J. Mol. Sci., 18, 545, 10.3390/ijms18030545 · DOI · Paper page
- Cragg GM, Pezzuto JM (2015) Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventative agents. Medical Principles and Practice 2016. 25(suppl 2):41–59 DOI: https://doi.org/10.1159/000443404. · DOI · Paper page
- Davatgaran-Taghipour, 2017, Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective, Int. J. Nanomedicine, 12, 2689, 10.2147/IJN.S131973 · DOI · Paper page
- Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A. A., McKhann, G. M., Yan, Y., Wang, C., Zhang, H., Molkentin, J. D., Gunn-Moore, F. J., Vonsattel, J. P., Arancio, O., Chen, J. X., … Yan, S. D. (2008). Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med., 14(10), 1097–105. · DOI · Paper page
- Emanuele, 2018, The double-edged sword profile of redox signaling: oxidative events as molecular switches in the balance between cell physiology and Cancer, Chem. Res. Toxicol., 31, 201, 10.1021/acs.chemrestox.7b00311 · DOI
- Esposito, 2013, Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?, CNS Neuroscience & Therapeutics, 19, 549, 10.1111/cns.12095 · DOI · Paper page
- Gruber, 2013, Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing, Biotechnol. Adv., 31, 563, 10.1016/j.biotechadv.2012.09.005 · DOI
- Guedes-Dias, 2013, Lysine deacetylases and mitochondrial dynamics in neurodegeneration, Biochim. Biophys. Acta, 1832, 1345, 10.1016/j.bbadis.2013.04.005 · DOI
- Hu, 2016, Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons, Biochem. Biophys. Res. Commun., 478, 174, 10.1016/j.bbrc.2016.07.071 · DOI
- Hu, 2017, A Mitocentric view of Alzheimer's disease, Mol. Neurobiol., 54, 6046, 10.1007/s12035-016-0117-7 · DOI
- Imlay, 2003, Pathways of oxidative damage, Annu. Rev. Microbiol., 57, 395, 10.1146/annurev.micro.57.030502.090938 · DOI · Paper page
- Johnson, 2008, The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration, Ann. N. Y. Acad. Sci., 1147, 61, 10.1196/annals.1427.036 · DOI · Paper page
- Kalogeris, 2014, Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning, Redox Biol., 2, 702, 10.1016/j.redox.2014.05.006 · DOI · Paper page
- Kuruva, 2017, Aqua-soluble DDQ reduces the levels of Drp1 and Aβ and inhibits abnormal interactions between Aβ and Drp1 and protects Alzheimer's disease neurons from Aβ- and Drp1-induced mitochondrial and synaptic toxicities, Hum. Mol. Genet., 26, 3375, 10.1093/hmg/ddx226 · DOI · Paper page
- Li, 2018, SIRT4 is the last puzzle of mitochondrial sirtuins, Bioorg. Med. Chem., 26, 3861, 10.1016/j.bmc.2018.07.031 · DOI · Paper page
- Lv, 2017, Daphnetin-mediated Nrf2 antioxidant signaling pathways ameliorate tert-butyl hydroperoxide (t-BHP)-induced mitochondrial dysfunction and cell death, Free Radic. Biol. Med., 106, 38, 10.1016/j.freeradbiomed.2017.02.016 · DOI
- Man, 2014, A review of pinealectomy-induced melatonin-deficient animal models for the study of etiopathogenesis of adolescent idiopathic scoliosis, Int. J. Mol. Sci., 15, 16484, 10.3390/ijms150916484 · DOI
- Manczak, 2012, Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease, Hum. Mol. Genet., 21, 5131, 10.1093/hmg/dds360 · DOI · Paper page
- Manczak, 2012, Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage, Hum. Mol. Genet., 21, 2538, 10.1093/hmg/dds072 · DOI · Paper page
- Manczak, 2011, Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage, Hum. Mol. Genet., 20, 2495, 10.1093/hmg/ddr139 · DOI · Paper page
- Manczak, 2016, Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease, Hum. Mol. Genet., 25, 5148
- Manczak, 2018, Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease, Hum. Mol. Genet., 27, 1332, 10.1093/hmg/ddy042 · DOI · Paper page
- Mansouri, 2001, Acute ethanol administration Oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants, J. Pharmacol. Exp. Ther., 298, 737, 10.1016/S0022-3565(24)29435-0 · DOI · Paper page
- Mao, 2012, Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension, Hum. Mol. Genet., 21, 2973, 10.1093/hmg/dds128 · DOI · Paper page
- Mao, 2013, MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis, Biochim. Biophys. Acta, 1832, 2322, 10.1016/j.bbadis.2013.09.005 · DOI · Paper page
- Matsunaga, 2015, Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis, PLoS One, 10, 10.1371/journal.pone.0123289 · DOI · Paper page
- Mlinac, 2016, Assessment of activities of daily living, self-care, and Independence, Arch. Clin. Neuropsychol., 31, 506, 10.1093/arclin/acw049 · DOI · Paper page
- Motyl, 2018, Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders, Mol. Neurobiol., 55, 727, 10.1007/s12035-016-0317-1 · DOI
- Nicholls, 2001, Enzymology and structure of catalases, Adv. Inorg. Chem., 51, 51, 10.1016/S0898-8838(00)51001-0 · DOI · Paper page
- Reddy, 2006, Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for Mitochondrially targeted antioxidant therapeutics, J. Biomed. Biotechnol., 2006
- Reddy, 2011, Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease, Brain Res., 1415, 136, 10.1016/j.brainres.2011.07.052 · DOI · Paper page
- Reddy, 2011, Mitochondria as a therapeutic target for aging and neurodegenerative diseases, Curr. Alzheimer Res., 8, 393, 10.2174/156720511795745401 · DOI · Paper page
- Reddy, 2010, Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases, Brain Res. Rev., 67, 103
- Reddy, 2016, Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease, Journal of investigative medicine: the official publication of the American Federation for Clinical Research, 64, 1220, 10.1136/jim-2016-000240 · DOI · Paper page
- Reddy, 2017, Chapter five – MicroRNAs, aging, cellular senescence, and Alzheimer's disease, Prog. Mol. Biol. Transl. Sci., 146, 127, 10.1016/bs.pmbts.2016.12.009 · DOI
- Reddy, 2018, Synergistic protective effects of mitochondrial division inhibitor 1 and mitochondria-targeted small peptide SS31 in Alzheimer's disease, Journal of Alzheimer's disease: JAD, 62, 1549, 10.3233/JAD-170988 · DOI · Paper page
- Scott, 2010, Mitochondrial fission and fusion, Essays Biochem., 47, 85, 10.1042/bse0470085 · DOI · Paper page
- Shields, 2015, Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons, Cell Death Dis., 6, e1725, 10.1038/cddis.2015.94 · DOI · Paper page
- Strobel, 2007, The importance of β-carotene as a source of vitamin a with special regard to pregnant and breastfeeding women, Eur. J. Nutr., 46, 1, 10.1007/s00394-007-1001-z · DOI
- Szeto, 2014, Serendipity and the discovery of novel compounds that restore mitochondrial plasticity, Clin. Pharmacol. Ther., 96, 672, 10.1038/clpt.2014.174 · DOI · Paper page
- Szeto, 2014, First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics, Br. J. Pharmacol., 171, 2029, 10.1111/bph.12461 · DOI · Paper page
- Tanila, 2016, The role of BDNF in Alzheimer's disease, Neurobiol. Dis., 97, 114
- Wilkins, 2016, Relationships between mitochondria and Neuroinflammation: implications for Alzheimer's disease, Curr. Top. Med. Chem., 16, 849, 10.2174/1568026615666150827095102 · DOI · Paper page
- Yan, 2005, Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD), Int. J. Exp. Pathol., 86, 161, 10.1111/j.0959-9673.2005.00427.x · DOI · Paper page
- Yin, 2016, Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease, Hum. Mol. Genet., 25, 1739, 10.1093/hmg/ddw045 · DOI · Paper page
Cited by
Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
Reddy, P. H., & Oliver, D. M. (2019) · Cells · doi:10.3390/cells8050488 · Cited by 496
“Factors such as oxidative damage, cytochrome c leakage from the IMM, Ca2+ release, loss of membrane potential, caspase activation, and mtDNA damage are signs of mitochondrial dysfunction, and precede selective autophagy [2,13,76,116].”
BackgroundInfluentialSelf-citationDefective mitophagy in Alzheimer’s disease
Pradeepkiran, J. A., & Reddy, P. H. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101191 · Cited by 367
Self-citationSun, Y., Huang, J., Chen, Y., Shang, H., Zhang, W., Yu, J., He, L., Xing, C., & Zhuang, C. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104172 · Cited by 73
Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles
Deng, Z., Dong, Y., Zhou, X., Lu, J.-H., & Yue, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.009 · Cited by 58
Bhatti, J. S., Tamarai, K., Kandimalla, R., Manczak, M., Yin, X., Ramasubramanian, B., Sawant, N., Pradeepkiran, J. A., Vijayan, M., Kumar, S., et al. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.007 · Cited by 30
Self-citation
Metadata
- Authors
- Oliver, D. M. A., & Reddy, P. H.
- Venue
- Molecular and Cellular Neuroscience
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 96
- Pages
- 47-62
- ISSN
- 1044-7431 (ISSN-L)
- OpenAlex
- W2921919999
- Cited by
- 156
- References
- 17
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institutes of Health (R01AG042178, R01AG047812, R01NS105473, R41AG060836)
- CH Foundation
- Garrison Family Foundation
- Alzheimer's Association
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small molecules as therapeutic drugs for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.mcn.2019.03.001
- The paper
- Oliver, D. M. A., & Reddy, P. H. (2019). Small molecules as therapeutic drugs for Alzheimer's disease. Molecular and Cellular Neuroscience. https://doi.org/10.1016/j.mcn.2019.03.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.